A randomized, double-blind, phase 2 trial of paclitaxel plus bevacizumab and enzastaurin versus paclitaxel plus bevacizumab and placebo for locally recurrent or metastatic breast cancer

Trial Profile

A randomized, double-blind, phase 2 trial of paclitaxel plus bevacizumab and enzastaurin versus paclitaxel plus bevacizumab and placebo for locally recurrent or metastatic breast cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Nov 2014

At a glance

  • Drugs Enzastaurin (Primary) ; Bevacizumab; Paclitaxel
  • Indications Advanced breast cancer; Male breast cancer
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 12 Aug 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Aug 2008 Actual patient number is changed from 120 to 2 as reported by ClinicalTrials.gov.
    • 12 Aug 2008 Actual end date is 1 March 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top